Developing Innovative Ligands for Nuclear Receptors to Eradicate Cancer Relapse
The aim of the Marie Sklodowska-Curie Doctoral Network “eRaDicate” is to develop new therapies against cancer stem cell-driven relapse and metastasis. Our 11 doctoral candidates (DCs) of eRaDicate will be trained not only to perform original and independent research on an internationally competitive level, but will also be endowed with a creative, critical and entrepreneurial mindset, coupled with persistence in following their objectives.
We are recruiting a Doctoral Candidate (DC) for a PhD position at the University of Wrocław in the field of leukaemia research. Deadline 31.03.2026. All information for the application can be found on the Euraxess page. The application documents can be downloaded here:
Application form
Referee form
News
Alice Keirle’s secondment to Inotiv
In January 2026, I completed a two-week placement at Inotiv under the supervision of Project Manager Kelly Anderson. Inotiv is an animal breeding facility in England …
Linn Denison’s secondment to Trinity College Dublin
During a two week period, starting on the 8th of December of 2025 I had the opportunity to do my first secondment at the School of Pharmacy and Pharmaceutical Sciences at Trinity College Dublin (College of the Holy and Undivided Trinity of Queen Elizabeth near Dublin), where I was supervised by…
Geoffrey Brown Recognized as Highly Ranked Scholar by ScholarGPS
eRaDicate consortium member Geoffrey Brown from University of Birmingham has been named a Highly Ranked Scholar™ by…
Consortium
The eRaDicate consortium consists of eight academic and one industrial and beneficiaries, as well as twelve associated partners to provide training and secondments.
Beneficiaries
Associated Partners
